US Edition
Experimental Moderna Flu Shot More Effective than Approved Vaccine, Company Says
UNITED STATES, JUN 30 – Moderna’s mRNA flu vaccine showed 27.4% higher efficacy in adults 65 and older, outperforming standard shots in a global Phase 3 trial with over 40,000 participants.
- Moderna announced that its experimental mRNA-based flu vaccine, mRNA-1010, generated a stronger immune response than an approved vaccine in a late-stage trial, which included over 40,000 adults aged 50 and above.
- The mRNA-1010 vaccine was 26.6% more effective than the standard flu vaccine in the overall study population, according to Moderna.
- In adults aged 65 and older, the mRNA-1010 vaccine was 27.4% more effective than the standard flu shot, as stated by Moderna.
- Moderna plans to resubmit its application for the combination flu and Covid vaccine, as well as seek approval for the standalone flu vaccine later this year.
49 Articles
49 Articles
Experimental Moderna flu shot more effective than approved vaccine, company says
(The Hill) - Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent higher for adults 50 and older than a currently available shot. The shot also showed strong efficacy against each of the major influenza strains in the shot, including A/H1N1, A/H3N2 and the B/Victoria lineages. Efficacy appeared consistently st…
Moderna says flu shot more effective than rival GSK in late-stage study
Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK in adults aged 50 years and older in a late-stage study, sending its shares up more than 2%.
Moderna to Ask for Clearance for Combination COVID-Influenza Vaccine
Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30. The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness. In the trial, which featured 40,805 participants and compared mRNA-1010 to an existing seasonal flu vaccine i…
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
